ABIONYX Pharma (EPA: ABNX) net income
ABIONYX Pharma reported a net loss of €5.6m for fiscal 2025; in fiscal 2024 it reported a net loss of €4.4m. Earnings per share were −€0.16.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −€5.6m | — | −136.6% | −€0.16 |
| 2024 | −€4.4m | — | −96.3% | −€0.13 |
| 2023 | −€3.5m | — | −75.8% | −€0.12 |
| 2022 | −€4.2m | — | −80.1% | −€0.15 |
| 2021 | −€5.8m | — | −862.5% | −€0.23 |
| 2020 | −€1.9m | −202.0% | — | — |
| 2019 | €1.8m | — | — | €0.09 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of euros, except per-share amounts.
Questions about the net income of ABIONYX Pharma
- How much did ABIONYX Pharma earn in fiscal 2025?
- ABIONYX Pharma reported a net loss of €5.6m for fiscal 2025. In fiscal 2024 it reported a net loss of €4.4m.
- What are the earnings per share of ABIONYX Pharma?
- They were −€0.16 in fiscal 2025, compared with −€0.13 in fiscal 2024.
- What was the most profitable year for ABIONYX Pharma?
- Of its last 7 fiscal years, fiscal 2019, with €1.8m.
- Where do the figures for ABIONYX Pharma come from?
- From the report ABIONYX Pharma files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
From the annual report ABIONYX Pharma files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2023 · 2022 · 2021 · 2020. More on ABIONYX Pharma: the ABIONYX Pharma page · annual accounts · revenue.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.